{Reference Type}: Editorial
{Title}: The combination of osimertinib and savolitinib as molecular inhibition of EGFR and MET receptors may be selected to provide maximum effectiveness and acceptable toxicity.
{Author}: Kowalski DM;Zaborowska-Szmit M;Szmit S;Jaśkiewicz P;Krzakowski M;
{Journal}: Transl Lung Cancer Res
{Volume}: 13
{Issue}: 6
{Year}: 2024 Jun 30
{Factor}: 4.726
{DOI}: 10.21037/tlcr-24-204